Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy

Progress in Cardiovascular Diseases

Volumn 45, Issue 4, 2003, Pages 305-318

  Lewis, William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DNA DIRECTED DNA POLYMERASE GAMMA; FIALURIDINE; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOMYOPATHY; DISEASE ASSOCIATION; DNA REPLICATION; GENE MUTATION; GENOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER FAILURE; MUSCLE ATROPHY; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYALGIA; OXIDATIVE STRESS; REVIEW; SIDE EFFECT;

EID: 0037217858     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2003.3b     Document Type: Review

References (149)

1. Wright GE, Brown NC: Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmacol Ther 47:447-497, 1990
2. Lewis W, Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nat Med 1:417-422, 1995
3. Swartz MN: Mitochondrial toxicity - new adverse drug effects [editorial;comment]. N Engl J Med 333:1099-1105, 1995
4. Brinkman K, Smeitink JA, Romijn JA, et al: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [comment]. Lancet 354:1112-1115, 1999
5. Kakuda TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity [in process citationl. Clin Ther 22:685-708, 2000
6. Kakuda TN, Brundage RC, Anderson PL, et al: Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy [letter]. AIDS 13:2311-2312, 1999
7. Lewis W, Copeland WC, Day B: Mitochondrial DNA depletion, oxidative stress and mutation: Mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Lab Invest 81:777-790, 2001
8. Boubaker K, Sudre P, Flepp M, et al: Hyperlactatemia and Antiretroviral Therapy in the Swiss HIV Cohort Study (SHCS). In the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000
9. Brinkman K: Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 31:167-169, 2000
10. Church J, Mitchell W, Gonzalez-Gomez I, et al: Near-fatal metabolic acidosis, liver failure in mitochondrial (mt) DNA depletion in an HIV-infected child treated with combination antiretroviral therapy (ART). In the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000
11. Gerard Y, Maulin L, Yazdanpanah Y, et al: Symptomatic hyperlactataemia: An emerging complication of antiretroviral therapy. AIDS 14:2723-2730, 2000
12. John M, Moore CB, James IR, et al: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15:717-723, 2001
13. Lonergan JT, Havlir D, Behling C, et al: Hyperlactatemia in 20 patients receiving NRTI combination regimens. In the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000
14. Mokrzycki MH, Harris C, May H, et al: Lactic acidosis associated with stavudine administration: A report of five cases. Clin Infect Dis 30:198-200, 2000
15. Olano JP, Borucki MJ, Wen JW, et al: Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 21:973-976, 1995
16. Shaer AJ, Rastegar A: Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature. Am J Nephrol 20:332-338, 2000
17. Tantisiriwat W, Tebas P, Polish LB, et al: Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses 17:195-201, 2001
18. Walker UA: Clinical manifestations of mitochondrial toxicity. J HIV Ther 6:17-21, 2001
19. Lewis W, Papoian T, Gonzalez B, et al: Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 65:228-236, 1991
20. Lewis W, Gonzalez B, Chomyn A, et al: Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 89:1354-1360, 1992
21. Lewis W: Pathologic changes in the hearts of patients with AIDS, in Lipshultz SE, ed. Cardiology in AIDS. New York: Chapman and Hall, 1998, pp 233-254
22. Brinkman K, ter Hofstede HJ, Burger DM, et al: Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway [editorial]. AIDS 12:1735-1744, 1998
23. Lewis W, Griniuviene B, Tankersley KO, et al: Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 76:77-87, 1997
24. Cote HC, Brumme ZL, Craib KJ, et al: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346:811-820, 2002
25. Lewis W, Haase CP, Raidel SM, et al: Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab Invest 81:1527-1536, 2001
26. Dalakas MC, Illa I, Pezeshkpour GH, et al: Mitochondrial myopathy caused by long-term zidovudine therapy [see comments]. N Engl J Med 322:1098-1105, 1990
27. Lamperth L, Dalakas MC, Dagani F, et al: Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest 65:742-751, 1991
28. Lewis W, Simpson JF, Meyer RR: Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 74:344-38, 1994
29. Konig H, Behr E, Lower J, et al: Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrob Agents Chemother 33:2109-2114, 1989
30. de la Asuncion JG, del Olmo ML, Sastre J, et al: AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 102:4-9, 1998
31. Bialkowska A, Bialkowski K, Gerschenson M, et al: Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT). Carcinogenesis 21:1059-1062, 2000
32. Choi J, Opalenik SR, Wu W, et al: Modulation of glutathione synthetic enzymes by acidic fibroblast growth factor. Arch Biochem Biophys 375:201-209, 2000
33. Choi J, Liu RM, Kundu RK, et al: Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem 275:3693-3698, 2000
34. Raidel SM, Haase C, Jansen NR, et al: Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol 282:H1672-H1678, 2002
35. Schapira AH, Cooper JM: Mitochondrial function in neurodegeneration and ageing. Mutat Res 275:133-143, 1992
36. Wallace DC: Diseases of the mitochondrial DNA. Annu Rev Biochem 61:1175-1212, 1992
37. Wernette CM, Kaguni LS: A mitochondrial DNA polymerase from embryos of Drosophila melanogaster. Purification, subunit structure, and partial characterization. J Biol Chem 261:14764-14770, 1986
38. Insdorf NF, Bogenhagen DF: DNA polymerase gamma from Xenopus laevis . I. The identification of a high molecular weight catalytic subunit by a novel DNA polymerase photolabeling procedure. J Biol Chem 264:21491-21497, 1989
39. Gray H, Wong TW: Purification and identification of subunit structure of the human mitochondrial DNA polymerase. J Biol Chem 267:5835-5841, 1992
40. Wang Y, Farr CL, Kaguni LS: Accessory subunit of mitochondrial DNA polymerase from Drosophila embryos. Cloning, molecular analysis, and association in the native enzyme. J Biol Chem 272:13640-13646, 1997
41. Carrodeguas JA, Kobayashi R, Lim SE, et al: The accessory subunit of Xenopus laevis mitochondrial DNA polymerase gamma increases processivity of the catalytic subunit of human DNA polymerase gamma and is related to class II aminoacyl-tRNA synthetases. Mol Cell Biol 19:4039-4046, 1999
42. Lim SE, Longley MJ, Copeland WC: The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance. J Biol Chem 274:38197-38203, 1999
43. Ponamarev MV, Longley MJ, Nguyen D, et al: Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis. J Biol Chem 15:15, 2002
44. Iyengar B, Luo N, Farr CL, et al: The accessory subunit of DNA polymerase gamma is essential for mitochondrial DNA maintenance and development in Drosophila melanogaster. Proc Natl Acad Sci U S A 99:4483-4488, 2002
45. Bogenhagen DF: Repair of mtDNA in vertebrates. Am J Hum Genet 64:1276-1281, 1999
46. Moraes CT, Shanske S, Tritschler HJ, et al: mtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 48:492-501, 1991
47. Wallace DC: Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science 256:628-632, 1992
48. Kunkel TA, Soni A: Exonucleolytic proofreading enhances the fidelity of DNA synthesis by chick embryo DNA polymerase-gamma. J Biol Chem 263:4450-4459, 1988
49. Kunkel TA, Mosbaugh DW: Exonucleolytic proof-reading by a mammalian DNA polymerase. Biochemistry 28:988-995, 1989
50. Kaguni LS, Wernette CM, Conway MC, et al: Structural and catalytic features of the mitochondrial DNA polymerase from Drosophila melanogaster embryos, in Eukaryotic DNA Replication. Cold Spring Harbor, NY: Cold Spring Harbor Laboratories, 1988, pp 425-432
51. Arnaudo E, Dalakas M, Shanske S, et al: Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337:508-510, 1991
52. Arner ES, Eriksson S: Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155-186, 1995
53. Nishino I, Spinazzola A, Hirano M: Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283:689-692, 1999
54. Saada A, Shaag A, Mandel H, et al: Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29:342-344, 2001
55. Katz AM: Is the failing heart energy depleted? Cardiol Clin 16:viii, 633-644, 1998
56. Wallace DC: Mitochondrial diseases in man and mouse. Science 283:1482-1488, 1999
57. Lewis W, Meyer RR, Simpson JF, et al: Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 33:14620-14624, 1994
58. Lewis W, Levine ES, Griniuviene B, et al: Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A 93:3592-3597, 1996
59. Lewis W, Grupp IL, Grupp G, et al: Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 80:187-197, 2000
60. Yamaguchi T, Katoh I, Kurata S: Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization. Eur J Biochem 269:2782-2788, 2002
61. Betteridge DJ: What is oxidative stress? Metabolism 49:3-8, 2000
62. Freeman BA, Crapo JD: Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 256:10986-10992, 1981
63. Boveris A, Chance B: The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 134:707-716, 1973
64. 2 release by lung mitochondria and microsomes. Arch Biochem Biophys 217:411-421, 1982
65. Nohl H, Jordan W, Hegner D: Mitochondrial formation of OH radicals by an ubisemiquinone-dependent reaction an alternative pathway to the iron-catalysed Haber-Weiss cycle. Hoppe Seylers Z Physiol Chem 363:599-607, 1982
66. Taylor DE, Ghio AJ, Piantadosi CA: Reactive oxygen species produced by liver mitochondria of rats in sepsis. Arch Biochem Biophys 316:70-76, 1995
67. Tangeras A, Flatmark T, Backstrom D, et al: Mitochondrial iron not bound in heme and iron-sulfur centers. Estimation, compartmentation and redox state. Biochim Biophys Acta 589:162-175, 1980
68. Flint DH, Tuminello JF, Emptage MH: The inactivation of Fe-S cluster containing hydro-lyases by superoxide. J Biol Chem 268:22369-22376, 1993
69. Lim SE, Copeland WC: Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 276:23616-23623, 2001
70. Brown GC: Nitric oxide as a competitive inhibitor of oxygen consumption in the mitochondrial respiratory chain. Acta Physiol Scand 168:667-674, 2000
71. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 271:C1424-C1437, 1996
72. Radi R, Beckman JS, Bush KM, et al: Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288:481-487, 1991
73. 2 injury. J Appl Physiol 63:359-367, 1987
74. Asayama K, Yokota S, Dobashi K, et al: Immunolocalization of cellular glutathione peroxidase in adult rat lungs and quantitative analysis after postembedding immunogold labeling. Histochem Cell Biol 105:383-389, 1996
75. Marinho HS, Antunes F, Pinto RE: Role of glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase in the reduction of lysophospholipid hydroperoxides. Free Radic Biol Med 22:871-883, 1997
76. Halliwell B, Gutteridge JM: The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med 8:89-193, 1985
77. Gerschenson M, Poirier MC: Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann N Y Acad Sci 918:269-281, 2000
78. Miquel J: An integrated theory of aging as a result of mitochondrial. 1991
79. Linnane AW, Marzuki S, Ozawa T, et al: Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1:642-645, 1989
80. Freese EB, Gerson J, Taber H, et al: Inactivating DNA alterations induced by peroxides and peroxide-producing agents. Mutat Res 4:517-531, 1967
81. Brawn K, Fridovich I: DNA strand scission by enzymically generated oxygen radicals. Arch Biochem Biophys 206:414-419, 1981
82. Szabo C, Day BJ, Salzman AL: Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. FEBS Lett 381:82-86, 1996
83. Spencer JP, Wong J, Jenner A, et al: Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine. Chem Res Toxicol 9:1152-1158, 1996
84. Cortopassi G, Liu Y, Hutchin T: Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Exp Gerontol 31:253-265, 1996
85. Richter C: Do mitochondrial DNA fragments promote cancer and aging? [see comments]. FEBS Lett 241:1-5, 1988
86. Richter C, Park JW, Ames BN: Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci U S A 85:6465-6467, 1988
87. Hayakawa M, Hattori K, Sugiyama S, et al: Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem Biophys Res Commun 189:979-985, 1992
88. Pavlov YI, Minnick DT, Izuta S, et al: DNA replication fidelity with 8-oxodeoxyguanosine triphosphate. Biochemistry 33:4695-4701, 1994
89. Yakes FM, Van Houten B: Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A 94:514-519, 1997
90. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 90:7915-7922, 1993
91. Pinz KG, Bogenhagen DF: Efficient repair of abasic sites in DNA by mitochondrial enzymes. Mol Cell Biol 18:1257-1265, 1998
92. Fleming JE, Miquel J, Cottrell SF, et al: Is cell aging caused by respiration-dependent injury to the mitochondrial genome? Gerontology 28:44-53, 1982
93. Kuchino Y, Mori F, Kasai H, et al: Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature 327:77-79, 1987
94. Hattori K, Tanaka M, Sugiyama S, et al: Age-dependent increase in deleted mitochondrial DNA in the human heart: Possible contributory factor to presbycardia. Am Heart J 121:1735-1742, 1991
95. Linnane AW, Zhang C, Baumer A, et al: Mitochondrial DNA mutation and the ageing process: Bioenergy and pharmacological intervention. Mutat Res 275:195-208, 1992
96. Muller-Hocker J: Cytochrome-c-oxidase deficient cardiomyocytes in the human heart - an age-related phenomenon. A histochemical ultracytochemical study. Am J Pathol 134:1167-1173, 1989
97. Parker WB, Cheng YC: Mitochondrial toxicity of NRTI analogs. J NIH Res 6:57-61, 1994
98. Feng JY, Johnson AA, Johnson KA, et al: Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 276:23832-23837, 2001
99. Fourel I, Hantz O, Watanabe KA, et al: Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 34:473-475, 1990
100. Eriksson S, Xu B, Clayton DA: Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem 270:18929-18934, 1995
101. Longley MJ, Mosbaugh DW: Properties of the 3′ to 5′ exonuclease associated with porcine liver DNA polymerase gamma. Substrate specificity, product analysis, inhibition, and kinetics of terminal excision. J Biol Chem 266:24702-24711, 1991
102. Lewis W, Tankersley KO: Triphosphorylated fialuridine and metabolites inhibit cardiac mitochondrial DNA polymerase gamma (DNA polymerase-gamma): Alternative substrates for thymidine triphosphate (dTTP). Circulation 92:1186, 1995
103. Gray NM, Marr CL, Penn CR, et al: The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmacol 50:1043-1051, 1995
104. Martin JL, Brown CE, Matthews-Davis N, et al: Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 38:2743-2749, 1994
105. Groopman JE: Zidovudine intolerance. Rev Infect Dis 12:S500-S506, 1990 (suppl 5)
106. Till M, MacDonell KB: Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Ann Intern Med 113:492-494, 1990
107. Shoubridge EA: Mitochondrial DNA diseases: Histological and cellular studies. J Bioenerg Biomembr 26:301-310, 1994
108. Pezeshkpour G, Illa I, Dalakas MC: Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies. Hum Pathol 22:1281-1288, 1991
109. Dalakas MC, Leon-Monzon ME, Bernardini I, et al: Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage [see comments]. Ann Neurol 35:482-487, 1994
110. Peters BS, Winer J, Landon DN, et al: Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. QJM 86:5-15, 1993
111. Jay C, Dalakas MC: Myopathies and neuropathies in HIV-infected adults and children, in Pizzo P, Wilfert CM, eds. Pediatric AIDS. Baltimore, MD: Williams and Wilkins, 1994, pp 559-573
112. Bessen LJ, Greene JB, Louie E, et al: Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC [letter]. N Engl J Med 318:708, 1988
113. Sinnwell TM, Sivakumar K, Soueidan S, et al: Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. J Clin Invest 96:126-131, 1995
114. Chariot P, Gherardi R: Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. Neuromuscul Disord 1:357-363, 1991
115. Chariot P, Monnet I, Mouchet M, et al: Determination of the blood lactate: pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum 37:583-586, 1994
116. Herskowitz A, Willoughby SB, Baughman KL, et al: Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases. Ann Intern Med 116:311-313, 1992
117. Felker GM, Thompson RE, Hare JM, et al: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy [see comments]. N Engl J Med 342:1077-1084, 2000
118. d'Amati G, Kwan W, Lewis W: Dilated cardiomyopathy in a zidovudine-treated AIDS patient. Cardiovasc Pathol 1:317-320, 1992
119. Lipshultz SE, Orav EJ, Sanders SP, et al: Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine [see comments]. N Engl J Med 327:1260-1265, 1992
120. Lipshultz SE, Easley KA, Orav EJ, et al: Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group [see comments]. N Engl J Med 343:759-766, 2000
121. Domanski MJ, Sloas MM, Follmann DA, et al: Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus [see comments]. J Pediatr 127:137-146, 1995
122. Gerschenson M, Erhart SW, Paik CY, et al: Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retro-viruses 16:635-644, 2000
123. Chen CH, Vazquez-Padua M, Cheng YC: Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 39:625-628, 1991
124. Simpson MV, Chin CD, Keilbaugh SA, et al: Studies on the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication. Biochem Pharmacol 38:1033-1036, 1989
125. Chen CH, Cheng YC: Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 264:11934-11937, 1989
126. d'Amati G, Lewis W: Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells. Lab Invest 71:879-884, 1994
127. Semino-Mora MC, Leon-Monzon ME, Dalakas MC: The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest 71:773-781, 1994
128. Corcuera Pindado MT, Lopez Bravo A, Martinez-Rodriguez R, et al: Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle. Eur J Histochem 38:311-318, 1994
129. Reyes MG, Casanova J, Varricchio F: Zidovudine mitochondriopathy of hamster quadriceps muscle. Lab Invest 64:89A, 1991 (abstr)
130. Brahams D: Deaths in US fialuridine trial [news]. Lancet 343:1494-1495, 1994
131. Marshall E: Hepatitis study. Drug trial deaths deemed unavoidable [news]. Science 264:1530, 1994
132. Macilwain C: US agencies split over inquiry into effects of radiation experiments [news]. Nature 368:781, 1994
133. Cui L, Yoon S, Schinazi RF, et al: Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 95:555-563, 1995
134. Levine ES, Lewis W: The thymidine analogs fialuridine and zidovidine inhibit mitochondrial energy metabolism in cultured hepatoblasts. FASEB J 9:A1398, 1995 (abstr)
135. Klecker RW, Katki AG, Collins JM: Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2′-fluoro-2′-deoxy-beta-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells. Mol Pharmacol 46:1204-1209, 1994
136. Tennant BC, Baldwin BH, Graham LA, et al: Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179-191, 1998
137. Freiman JP, Helfert KE, Hamrell MR, et al: Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7:379-385, 1993
138. Chattha G, Arieff AI, Cummings C, et al: Lactic acidosis complicating the acquired immunodeficiency syndrome [see comments]. Ann Intern Med 118:37-39, 1993
139. Jolliet P, Widmann JJ: Reye's syndrome in adult with AIDS [letter]. Lancet 335:1457, 1990
140. Moore R, Keruly J, Chaisson R: Differences in anion gap with different nucleoside RTI combinations. In the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000
141. Ter Hofstede H, De Marie S, Foudraine N, et al: Four cases of fatal lactic acidosis due to mitochondrial toxicity of NRTI treatment: Analysis of clinical features and risk factors. In the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000
142. Saint-Marc T, Partisani M, Poizot-Martin I, et al: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13:1659-1667, 1999
143. Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100:2153-2157, 1997
144. Sutliff RL, Diakalov S, Parker J, et al: Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circ Physiol 283:H2363-H2370, 2002
145. Cohen P, Sande M, Volberding P: The AIDS knowledge base: A textbook on HIV disease from the University of California, San Francisco. 2nd ed. Boston: Little Brown and Company, 1994
146. Lange J: Combination antiretroviral therapy. Back to the future. Drugs 49:32-40, 1995
147. De Clercq E: In search of a selective antiviral chemotherapy. Clin Microbiol Rev 10:674-693, 1997
148. De Clercq E: Antiviral drugs: Current state of the art. J Clin Virol 22:73-89, 2001
149. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Department of Health and Human Services, NIH, Bethesda, MD, 1999